Background
Lymphatics are important for their conduit functions of transporting antigen, immune cells, and inflammatory mediators to draining lymph nodes and to the general circulation. Lymphangiogenesis is involved in many pathologic processes; however, the roles for lymphatic responses in transplantation have not been thoroughly investigated.
Methods
Mice were made diabetic by a single high dose of streptozotocin and then received islet allografts. Animals were treated with three different lymphatic inhibitors. FTY720, an analog of sphingosine 1-phosphate, inhibited lymphocyte migration into afferent and efferent lymphatics. Sunitinib, a kinase inhibitor, blocked several receptors, including vascular endothelial growth factor receptor 3 (VEGFR3), the major growth factor receptor for lymphatic endothelial cells. Anti-VEGFR3 monoclonal antibody specifically inhibited VEGFR3. Diabetes was determined by daily monitoring of blood glucose levels. Inflammation within islet grafts was assessed by immunohistochemistry for insulin, T cells (CD3), and lymphatics (LYVE-1).
Results
After transplantation, lymphangiogenesis occurred in islet allografts and in draining lymph nodes. FTY720, sunitinib, and anti-VEGFR3 each inhibited lymphangiogenesis in the islets and significantly prolonged allograft survival. Immunofluorescent staining demonstrated that administration of each of the lymphatic inhibitors resulted in preservation of islets and β-cells along with a markedly reduced infiltration of T cells into the grafts.
Conclusion
Lymphangiogenesis occurs in islet allografts in response to inflammation and plays a key role in the islet inflammation in alloimmunity. Interfering with lymphatic function leads to inhibition of lymphangiogenesis and prolonged or indefinite allograft survival. These observations suggest new therapeutic targets for rejection and tolerance.
Nitrogen oxides (NO
x
) play a key role
in regulating the oxidizing capacity of the atmosphere through controlling
the abundance of O3, OH, and other important gas and particle
species. Some recent studies have suggested that particulate nitrate,
which is conventionally considered as the ultimate oxidation product
of NO
x
, can undergo “renoxification”
via photolysis, recycling NO
x
and HONO
back to the gas phase. However, there are large discrepancies in estimates
of the importance of this channel, with reported renoxification rate
constants spanning three orders of magnitude. In addition, previous
laboratory studies derived the rate constant using bulk particle samples
collected on substrates instead of suspended particles. In this work,
we study renoxification of suspended submicron particulate sodium
and ammonium nitrate through controlled laboratory photolysis experiments
using an environmental chamber. We find that, under atmospherically
relevant wavelengths and relative humidities, particulate inorganic
nitrate releases NO
x
and HONO less than
10 times as rapidly as gaseous nitric acid, putting our measurements
on the low end of recently reported renoxification rate constants.
To the extent that our laboratory conditions are representative of
the real atmosphere, renoxification from the photolysis of inorganic
particulate nitrate appears to play a limited role in contributing
to the NO
x
and OH budgets in remote environments.
These results are based on simplified model systems; future studies
should investigate renoxification of more complex aerosol mixtures
that represent a broader spectrum of aerosol properties to better
constrain the photolysis of ambient aerosols.
Isoflurane-mediated enhancement of GABA-triggered [Ca2+]i release results from membrane depolarization with subsequent activation of VDCCs and further Ca2+-induced Ca2+ release from the ryanodine-sensitizing Ca2+ store. An increase in [Ca2+]i, caused by activation of the GABAA receptor and opening of VDCCs, is necessary for isoflurane-induced calcium overload of immature rat hippocampal neurons, which may be involved in the mechanism of an isoflurane-induced neurotoxic effect in the developing rodent brain.
The G protein-coupled receptor 55 (GPR55) is a novel cannabinoid receptor, whose exact role in anxiety remains unknown. The present study was conducted to explore the possible mechanisms by which GPR55 regulates anxiety and to evaluate the effectiveness of O-1602 in the treatment of anxiety-like symptoms. Mice were exposed to two types of acute stressors: restraint and forced swimming. Anxiety behavior was evaluated using the elevated plus maze and the open field test. We found that O-1602 alleviated anxiety-like behavior in acutely stressed mice. We used lentiviral shRNA to selectively knockdown GPR55 in the medial orbital cortex and found that knockdown of GPR55 abolished the anxiolytic effect of O-1602. We also used Y-27632, a specific inhibitor of ROCK, and U73122, an inhibitor of PLC, and found that both inhibitors attenuated the effectiveness of O-1602. Western blot analysis revealed that O-1602 downregulated the expression of GluA1 and GluN2A in mice. Taken together, these results suggest that GPR55 plays an important role in anxiety and O-1602 may have therapeutic potential in treating anxiety-like symptoms.
A microwave-assisted regioselective reaction dealing with arylglyoxal monohydrate, diverse N-aryl enaminones, and indoles to achieve 3,2'- and 3,3'-bis-indoles by varying a substituted indole substrate is reported. The 2-unsubstituted indoles resulted in the 3,2'-bis-indole skeleton, whereas indoles bearing a methyl or phenyl group at C2 led to the 3,3'-bis-indoles with simultaneous formation of three sigma-bonds. The procedures feature excellent regioselectivity, short reaction times, convenient one-pot manner, and operational simplicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.